文献速递糖尿病

达格列净对1型糖尿病激素调节和酮生成的影响:一项随机对照交叉试验

Dapagliflozin's impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial.
PubMed 文献 · Diabetologia · 2025-07-09

该随机、安慰剂对照、开放标签交叉试验纳入13例1型糖尿病患者,比较达格列净10 mg/日与安慰剂各7天对GLP-1、胰高血糖素、生长抑素和酮体的影响。结果显示达格列净未显著改变GLP-1、胰高血糖素或生长抑素浓度,但显著升高血浆酮体浓度,提示辅助使用达格列净时糖尿病酮症酸中毒风险升高。

要点

  • 达格列净未显著改变OGTTC或HEC期间GLP-1、胰高血糖素、生长抑素浓度。
  • 达格列净显著升高HEC和OGTTC期间血浆酮体浓度(p<0.001)。
  • 短期达格列净治疗在1型糖尿病中升高酮体,提示糖尿病酮症酸中毒风险升高。

核心结论

  • 短期达格列净治疗在1型糖尿病中升高血浆酮体浓度,但不影响GLP-1、胰高血糖素或生长抑素的分泌。
  • 较高的酮体浓度突显了辅助使用达格列净相关的糖尿病酮症酸中毒风险升高。

研究设计与样本

  • 随机、安慰剂对照、开放标签、交叉干预研究,设两个治疗期(达格列净和安慰剂),来自伯尔尼大学医院Inselspital糖尿病、内分泌、临床营养与代谢科的患者。
  • 纳入1型糖尿病患者(C肽浓度<0.1 nmol/l),病程>5年,BMI 20-29 kg/m2。
  • 受试者每日接受达格列净10 mg或安慰剂,每个治疗期7天,两个独立治疗期间隔14天洗脱期。
  • 分配由计算机随机化工具(REDCap)完成,参与者和研究者均未设盲。
  • 每个治疗期第7天进行高胰岛素-正常血糖钳夹(HEC)和OGTT钳夹(OGTTC),评估GLP-1、胰高血糖素、生长抑素和总酮体分泌变化。

主要发现

  • OGTTC期间GLP-1浓度两治疗间无显著差异(中位数[IQR]达格列净192.8 [129.8-257.2] pmol/l vs 安慰剂176.3 [138.4-227.4] pmol/l;p=0.7)。
  • HEC期间GLP-1浓度两治疗间无显著差异(中位数[IQR]达格列净208.6 [133.6-294.0] pmol/l vs 安慰剂203.1 [150.2-291.8] pmol/l;p=0.7)。
  • OGTTC期间胰高血糖素浓度两治疗间无显著差异(中位数[IQR]达格列净1.54 [0.84-3.68] ng/l vs 安慰剂1.54 [0.82-4.64] ng/l;p=0.8)。
  • HEC期间胰高血糖素浓度两治疗间无显著差异(中位数[IQR]达格列净1.59 [0.87-3.54] ng/l vs 安慰剂1.63 [0.91-3.96] ng/l;p=0.3)。
  • HEC期间生长抑素浓度两治疗间相当(中位数[IQR]达格列净41.1 [26.8-73.8] pmol/l vs 安慰剂47.0 [23.0-77.6] pmol/l;p=0.2);OGTTC期间亦相当(中位数[IQR]达格列净51.1 [31.1-77.0] pmol/l vs 安慰剂45.3 [30.0-70.5] pmol/l;p=0.2)。

关键数值与推荐

  • 主要终点为OGTTC期间GLP-1浓度。
  • 次要终点包括HEC期间GLP-1以及OGTTC和HEC期间胰高血糖素、生长抑素和酮体浓度。
  • 纳入标准:C肽浓度<0.1 nmol/l,病程>5年,BMI 20-29 kg/m2。
  • 干预剂量:达格列净10 mg每日一次,安慰剂每日一次,各7天,洗脱期14天。
  • 临床试验注册号:ClinicalTrials.gov NCT04035031。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: This study aimed to assess the impact of adding dapagliflozin to insulin therapy on key hormonal determinants of glucose regulation and ketogenesis. We hypothesise that dapagliflozin increases glucagon-like peptide 1 (GLP-1), glucagon and ketone body concentrations, based on the results of a pilot study. METHODS: The study was designed as a randomised, placebo-controlled, open-label, crossover intervention study with two periods (dapagliflozin and placebo intake), including patients of the Department of Diabetes, Endocrinology, Clinical Nutrition & Metabolism, Inselspital, Bern University Hospital, University of Bern. Individuals with type 1 diabetes (C-peptide concentrations <0.1 nmol/l) with a duration >5 years and a BMI of 20-29 kg/m2 were included. They received 10 mg of dapagliflozin or placebo daily for 7 days throughout two independent treatment periods, separated by a 14 day washout period. Allocation was done by a computed randomisation tool (REDCap), without blinding of the participants or the investigators. On day 7 of each treatment period, hyperinsulinaemic-euglycaemic clamps (HECs) and OGTT clamps (OGTTCs) were performed to assess changes in the secretion of GLP-1, glucagon, somatostatin and total ketone bodies. The objective was to evaluate the effects of adding the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin to insulin therapy on GLP-1 during OGTTC (primary endpoint), GLP-1 secretion during HEC, and glucagon, somatostatin and ketogenesis during OGTTC and HEC (secondary endpoints). The primary endpoint was concentrations of GLP-1 during OGTTC. Secondary endpoints included GLP-1 during HEC and glucagon, somatostatin and ketone body concentrations during OGTTC and HEC. RESULTS: A total of 13 individuals with type 1 diabetes were included and randomised. All of them received dapagliflozin and placebo, finished the sequences per protocol and were analysed per protocol. GLP-1 concentrations did not differ significantly between treatments in the OGTTC (median [IQR] dapagliflozin 192.8 [129.8-257.2] pmol/l vs placebo 176.3 [138.4-227.4] pmol/l; p=0.7) or HEC (median [IQR] dapagliflozin 208.6 [133.6-294.0] pmol/l vs placebo 203.1 [150.2-291.8] pmol/l; p=0.7). Glucagon concentrations did not significantly differ between treatments in the OGTTC (median [IQR] dapagliflozin 1.54 [0.84-3.68] ng/l vs placebo 1.54 [0.82-4.64] ng/l; p=0.8) or HEC (median [IQR] dapagliflozin 1.59 [0.87-3.54] ng/l vs placebo 1.63 [0.91-3.96] ng/l; p=0.3). Somatostatin concentrations remained comparable between treatments during the HEC (median [IQR] dapagliflozin 41.1 [26.8-73.8] pmol/l vs placebo 47.0 [23.0-77.6] pmol/l; p=0.2) and OGTTC (median [IQR] dapagliflozin 51.1 [31.1-77.0] pmol/l vs placebo 45.3 [30.0-70.5] pmol/l; p=0.2). Plasma ketone bodies were higher with dapagliflozin during the HEC (median [IQR] dapagliflozin 0.15 [0.04-0.47] mmol/l vs placebo 0.03 [0.01-0.12] mmol/l; p<0.001) and OGTTC (median [IQR] dapagliflozin 0.10 [0.03-0.22] mmol/l vs placebo 0.03 [0.01-0.12] mmol/l; p<0.001). CONCLUSIONS/INTERPRETATION: Short-term dapagliflozin treatment in type 1 diabetes increases plasma ketone concentrations without affecting the secretion of GLP-1, glucagon or somatostatin. Higher ketone body concentrations highlight the elevated risk of diabetic ketoacidosis associated with the adjunct intake of dapagliflozin. TRIAL REGISTRATION: ClinicalTrials.gov NCT04035031. FUNDING: Swiss National Science Foundation, project number 32003B_185019.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gübeli A, Steiner N, Limacher A, et al. Dapagliflozin's impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial. Diabetologia. 2025. PMID: 40629004. doi:10.1007/s00125-025-06481-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。